drugset / Trial / NCT04886284

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT04886284

Phase 2 Recruiting 60 enrolled Todd C. Lee MD MPH FIDSA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Timeline

Start
2024-05-20
Primary completion
2027-04
Completion
2027-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ertapenem Small molecule 1 g Intravenous